1. Academic Validation
  2. Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis

Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis

  • J Med Chem. 2018 Apr 26;61(8):3685-3696. doi: 10.1021/acs.jmedchem.8b00190.
Elnaz Menhaji-Klotz 1 Kevin D Hesp 2 Allyn T Londregan 2 Amit S Kalgutkar 1 David W Piotrowski 2 Markus Boehm 1 Kun Song 1 Tim Ryder 2 Kevin Beaumont 1 Rhys M Jones 1 Karen Atkinson 2 Janice A Brown 2 John Litchfield 1 Jun Xiao 2 Daniel P Canterbury 2 Kristen Burford 2 Benjamin A Thuma 2 Chris Limberakis 2 Wenhua Jiao 2 Scott W Bagley 2 Saket Agarwal 1 Danielle Crowell 1 Stephen Pazdziorko 1 Jessica Ward 1 David A Price 1 Valerie Clerin 1
Affiliations

Affiliations

  • 1 Pfizer Worldwide Research & Development , Cambridge , Massachusetts 02139 , United States.
  • 2 Pfizer Worldwide Research & Development , Groton , Connecticut 06340 , United States.
Abstract

C-X-C Chemokine Receptor type 7 (CXCR7) is involved in cardiac and immune pathophysiology. We report the discovery of a novel 1,4-diazepine CXCR7 Modulator, demonstrating for the first time the role of pharmacological CXCR7 intervention in cardiac repair. Structure-activity-relationship (SAR) studies demonstrated that a net reduction in lipophilicity (log D) and an incorporation of saturated ring systems yielded compounds with good CXCR7 potencies and improvements in oxidative metabolic stability in human-liver microsomes (HLM). Tethering an ethylene amide further improved the selectivity profile (e.g., for compound 18, CXCR7 Ki = 13 nM, adrenergic α 1a Kb > 10 000 nM, and adrenergic β 2 Kb > 10 000 nM). The subcutaneous administration of 18 in mice led to a statistically significant increase in circulating concentrations of plasma stromal-cell-derived factor 1α (SDF-1α) of approximately 2-fold. Chronic dosing of compound 18 in a mouse model of isoproterenol-induced cardiac injury further resulted in a statistically significant reduction of cardiac fibrosis.

Figures
Products